Nicotinamide drives T cell activation in the mammary tumor microenvironment

Nicotinamide (NAM, a variant of vitamin B(3)) has recently been shown to accelerate the activation of human CD4(+) and CD8(+) T cells exposed to repeated CD3/CD28 agonism in vitro. Here, we demonstrate that T cells infiltrating mouse mammary carcinomas that are therapeutically controlled by NAM also...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Yang, Bloy, Norma, Elemento, Olivier, Buqué, Aitziber
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164530/
https://www.ncbi.nlm.nih.gov/pubmed/35659314
http://dx.doi.org/10.1186/s12967-022-03454-z
_version_ 1784720155397324800
author Hu, Yang
Bloy, Norma
Elemento, Olivier
Buqué, Aitziber
author_facet Hu, Yang
Bloy, Norma
Elemento, Olivier
Buqué, Aitziber
author_sort Hu, Yang
collection PubMed
description Nicotinamide (NAM, a variant of vitamin B(3)) has recently been shown to accelerate the activation of human CD4(+) and CD8(+) T cells exposed to repeated CD3/CD28 agonism in vitro. Here, we demonstrate that T cells infiltrating mouse mammary carcinomas that are therapeutically controlled by NAM also express multiple markers of late-stage activation. Taken together, these findings lend additional support to the notion that the antineoplastic effects of NAM involve at least some degree of restored cancer immunosurveillance. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-022-03454-z.
format Online
Article
Text
id pubmed-9164530
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-91645302022-06-05 Nicotinamide drives T cell activation in the mammary tumor microenvironment Hu, Yang Bloy, Norma Elemento, Olivier Buqué, Aitziber J Transl Med Letter to the Editor Nicotinamide (NAM, a variant of vitamin B(3)) has recently been shown to accelerate the activation of human CD4(+) and CD8(+) T cells exposed to repeated CD3/CD28 agonism in vitro. Here, we demonstrate that T cells infiltrating mouse mammary carcinomas that are therapeutically controlled by NAM also express multiple markers of late-stage activation. Taken together, these findings lend additional support to the notion that the antineoplastic effects of NAM involve at least some degree of restored cancer immunosurveillance. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-022-03454-z. BioMed Central 2022-06-03 /pmc/articles/PMC9164530/ /pubmed/35659314 http://dx.doi.org/10.1186/s12967-022-03454-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Letter to the Editor
Hu, Yang
Bloy, Norma
Elemento, Olivier
Buqué, Aitziber
Nicotinamide drives T cell activation in the mammary tumor microenvironment
title Nicotinamide drives T cell activation in the mammary tumor microenvironment
title_full Nicotinamide drives T cell activation in the mammary tumor microenvironment
title_fullStr Nicotinamide drives T cell activation in the mammary tumor microenvironment
title_full_unstemmed Nicotinamide drives T cell activation in the mammary tumor microenvironment
title_short Nicotinamide drives T cell activation in the mammary tumor microenvironment
title_sort nicotinamide drives t cell activation in the mammary tumor microenvironment
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164530/
https://www.ncbi.nlm.nih.gov/pubmed/35659314
http://dx.doi.org/10.1186/s12967-022-03454-z
work_keys_str_mv AT huyang nicotinamidedrivestcellactivationinthemammarytumormicroenvironment
AT bloynorma nicotinamidedrivestcellactivationinthemammarytumormicroenvironment
AT elementoolivier nicotinamidedrivestcellactivationinthemammarytumormicroenvironment
AT buqueaitziber nicotinamidedrivestcellactivationinthemammarytumormicroenvironment

Ejemplares similares